UK's Compass Pathways Q1 operating income beats estimates as expenses fall

COMPASS Pathways

13/05/2026 11:39

Overview

UK mental health biotech's Q1 operating income beat analyst expectations as expenses declined

Company posted net income of $91.2 mln, driven by non-cash warrant revaluation gain

Cash position rose to $466 mln, expected to fund operations into 2028

Outlook

COMPASS Pathways expects final NDA submission for COMP360 in Q4 2026

Company anticipates 26-week data from COMP006 trial in early Q3 2026

COMPASS Pathways expects cash position to fund operations into 2028

Result Drivers

WARRANT REVALUATION GAIN - Net income was primarily driven by a $130.9 mln non-cash gain on fair value adjustment related to warrants, as the fair value fluctuates with share price

LOWER OPERATING EXPENSES - Research and development and general and administrative expenses declined due to lower clinical trial costs and reduced legal/professional fees

Company press release: ID:nBwKwkXca

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
$0.71
Q1 Net Income
$91.20 mln
Q1 Operating Income
Beat
-$42.90 mln
-$47.06 mln (9 Analysts)
Q1 Operating Expenses
$42.90 mln
Q1 Pretax Profit
$91.19 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Compass Pathways PLC is $18.00, about 92.1% above its May 12 closing price of $9.37

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)